Corneal Neovascularization: An Anti-VEGF Therapy Review
Top Cited Papers
Open Access
- 1 September 2012
- journal article
- review article
- Published by Elsevier BV in Survey of Ophthalmology
- Vol. 57 (5), 415-429
- https://doi.org/10.1016/j.survophthal.2012.01.007
Abstract
No abstract availableThis publication has 126 references indexed in Scilit:
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2011
- Novel aspects of corneal angiogenic and lymphangiogenic privilegeProgress in Retinal and Eye Research, 2010
- Topical Bevacizumab in the Treatment of Corneal NeovascularizationAmerican Journal of Ophthalmology, 2009
- Characteristics and Outcomes of Adult Patients Lost to Follow-Up at an Antiretroviral Treatment Clinic in Johannesburg, South AfricaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- Antiangiogene Therapie am vorderen AugenabschnittDer Ophthalmologe, 2007
- Corneal avascularity is due to soluble VEGF receptor-1Nature, 2006
- Killing the messenger: short RNAs that silence gene expressionNature Reviews Molecular Cell Biology, 2003
- The biology of VEGF and its receptorsNature Medicine, 2003
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Tumor Angiogenesis: Therapeutic ImplicationsThe New England Journal of Medicine, 1971